Compare Stocks → FW: 234x Gain (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:HCYTDOTCMKTS:LENSFNASDAQ:MOTSOTCMKTS:QTXB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCYTDH-CYTE$2.02-49.5%$2.02$2.02▼$77.00$521K1.12103 shs400 shsLENSFPresbia$0.02$0.02$0.00▼$0.19$257K5.915,650 shsN/AMOTSMotus GI$0.07$0.40$0.05▼$23.40$362K1.51.28 million shs135,649 shsQTXBQuantRx Biomedical$0.00$0.00$0.00▼$0.01$315K-1.97N/AN/A10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCYTDH-CYTE0.00%0.00%0.00%0.00%0.00%LENSFPresbia0.00%0.00%0.00%0.00%0.00%MOTSMotus GI0.00%-11.11%-83.86%-88.57%-99.38%QTXBQuantRx Biomedical0.00%0.00%0.00%-18.37%-6.98%Never use this word on your phone (FBI could be watching) (Ad)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...Watch my unredacted video about what I think is coming next right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHCYTDH-CYTEN/AN/AN/AN/AN/AN/AN/AN/ALENSFPresbiaN/AN/AN/AN/AN/AN/AN/AN/AMOTSMotus GI1.3124 of 5 stars3.53.00.00.01.10.00.6QTXBQuantRx BiomedicalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHCYTDH-CYTEN/AN/AN/AN/ALENSFPresbiaN/AN/AN/AN/AMOTSMotus GI3.00Buy$28.8840,004.17% UpsideQTXBQuantRx BiomedicalN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHCYTDH-CYTE$1.61M0.32N/AN/A($31.45) per share-0.06LENSFPresbiaN/AN/AN/AN/AN/AN/AMOTSMotus GI$320K1.13N/AN/A$1.74 per share0.04QTXBQuantRx BiomedicalN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHCYTDH-CYTE-$4.80MN/A0.00∞N/A-450.40%N/A-777.68%N/ALENSFPresbiaN/AN/A0.00∞N/AN/AN/AN/AN/AMOTSMotus GI-$12.87M-$28.55N/A∞N/A-4,033.54%N/A-110.70%5/8/2024 (Estimated)QTXBQuantRx Biomedical-$260KN/A0.00∞N/AN/AN/AN/AN/ALatest HCYTD, MOTS, QTXB, and LENSF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023MOTSMotus GIN/A-$4.13-$4.13-$3.78N/A$0.06 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHCYTDH-CYTEN/AN/AN/AN/AN/ALENSFPresbiaN/AN/AN/AN/AN/AMOTSMotus GIN/AN/AN/AN/AN/AQTXBQuantRx BiomedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHCYTDH-CYTEN/A0.120.12LENSFPresbiaN/AN/AN/AMOTSMotus GI0.461.761.69QTXBQuantRx BiomedicalN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipHCYTDH-CYTEN/ALENSFPresbiaN/AMOTSMotus GI20.06%QTXBQuantRx BiomedicalN/AInsider OwnershipCompanyInsider OwnershipHCYTDH-CYTE5.24%LENSFPresbia74.20%MOTSMotus GI1.57%QTXBQuantRx Biomedical21.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableHCYTDH-CYTE8258,000244,000Not OptionableLENSFPresbia2017.12 millionN/ANot OptionableMOTSMotus GI155.03 million4.95 millionNot OptionableQTXBQuantRx BiomedicalN/A78.70 million61.46 millionNot OptionableHCYTD, MOTS, QTXB, and LENSF HeadlinesSourceHeadlineQuantrx Biomedical Corp QTXBmorningstar.com - April 17 at 10:09 PMBiomedical Research Centreicr.ac.uk - October 21 at 2:17 PMNanomedicines and Biomedical Engineeringhelsinki.fi - October 12 at 8:46 AMBSc Biomedical Sciences / Overviewmanchester.ac.uk - October 7 at 5:12 PMBiomedical engineering articles from across Nature Portfolionature.com - September 23 at 10:43 PMThe Best Places to Be a Biomedical Engineer: Minneapolismddionline.com - August 29 at 3:15 PMWyoming INBRE Phase 4uwyo.edu - August 11 at 1:16 AMUMaine receives $11.3 million to support biomedical researchwabi.tv - April 1 at 7:18 PMBiomedical Science (Medical Microbiology) MScqmul.ac.uk - March 21 at 7:12 PMJinxiang Xiuml.edu - March 16 at 10:06 AMCausal Inference for Statistics, Social, and Biomedical Sciencescambridge.org - March 15 at 1:29 PMGlobal Biomedical Tester Market Research Report 2022-2032finance.yahoo.com - February 12 at 12:56 PMLifecore Biomedical receives non-compliance notice from Nasdaqseekingalpha.com - January 14 at 12:54 AM$100 million donation to UF Scripps Biomedical Research Institute in Jupiterpalmbeachpost.com - October 15 at 3:25 PMBiological and Biomedical Sciencesqmul.ac.uk - October 8 at 7:18 AMQTXB.PK - | Stock Price & Latest News | Reutersreuters.com - September 14 at 8:52 PMQuantrx Biomedical (OTC:QTXB), Earnings Estimates, EPS, and Revenuebenzinga.com - July 19 at 11:34 PMQuantrx Biomedical (OTC:QTXB), Analyst Ratings, Price Targets, Predictionsbenzinga.com - July 19 at 11:34 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsH-CYTEOTCMKTS:HCYTDH-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.PresbiaOTCMKTS:LENSFPresbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in the United States, South Korea, Australia, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland.Motus GINASDAQ:MOTSMotus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.QuantRx BiomedicalOTCMKTS:QTXBQuantRx Biomedical Corporation engages in the development and commercialization of patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its products include InSync, a feminine hygienic interlabial pad; Unique miniform, a treated pad for the temporary relief of the itch and discomfort associated with hemorrhoids and minor vaginal infection, as well as an untreated pad for the daily protection of light urinary, vaginal, or anal leakage; and other treated miniform products. QuantRx Biomedical Corporation was incorporated in 1986 and is based in Tualatin, Oregon. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.